Molbio Diagnostics Ltd vs Thyrocare Technologies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Molbio Diagnostics Ltd is ₹ 1237 as of 23 Oct 15:30 . The P/E Ratio of Molbio Diagnostics Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Thyrocare Technologies Ltd changed from 42.2 on March 2021 to 34.2 on March 2026 . This represents a CAGR of -3.44% over 6 years The Market Cap of Molbio Diagnostics Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Thyrocare Technologies Ltd changed from ₹ 4774 crore on March 2021 to ₹ 5566 crore on March 2026 . This represents a CAGR of 2.59% over 6 years The revenue of Molbio Diagnostics Ltd for the Jun '26 is ₹ 411.48 crore as compare to the Mar '26 revenue of ₹ 565.41 crore. This represent the decline of -27.22% The revenue of Thyrocare Technologies Ltd for the Jun '26 is ₹ 244.88 crore as compare to the Mar '26 revenue of ₹ 228.84 crore. This represent the growth of 7.01% The ebitda of Molbio Diagnostics Ltd for the Jun '26 is ₹ 103.68 crore as compare to the Mar '26 ebitda of ₹ 163.51 crore. This represent the decline of -36.59% The ebitda of Thyrocare Technologies Ltd for the Jun '26 is ₹ 82.13 crore as compare to the Mar '26 ebitda of ₹ 79.98 crore. This represent the growth of 2.69% The net profit of Molbio Diagnostics Ltd changed from ₹ -23.94 crore to ₹ 52.74 crore over 5 quarters. This represents a CAGR of NaN% The net profit of Thyrocare Technologies Ltd changed from ₹ 23.94 crore to ₹ 51.33 crore over 9 quarters. This represents a CAGR of 40.35% The Dividend Payout of Molbio Diagnostics Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Thyrocare Technologies Ltd changed from 110.36 % on March 2021 to 149.75 % on March 2026 . This represents a CAGR of 5.22% over 6 years .

About Molbio Diagnostics Ltd

Molbio Diagnostics Limited was originally incorporated as Molbio Diagnostics Private Limited' at Panaji, as a private company dated October 20, 2000.
Thereafter, Company was converted from a private limited company to a public limited company, and the name of Company was changed to Molbio Diagnostics Limited, and a fresh certificate of incorporation dated January 16, 2025 was issued to Company by the RoC. Company is innovative point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases.
The Company entered into a joint venture agreement in August, 2011 with Bigtec Innovations Private Limited and Bigtec Private Limited, which started operations in 2000.
Bigtec Innovations Private Limited got merged with the Company in 2015.

About Thyrocare Technologies Ltd

Thyrocare Technologies Limited was incorporated in January, 2000.
The Company operates in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India. As of 31 March 2025, the Company offered more than 920 distinct tests that support early detection, preventive care and the ongoing disease monitoring.
Their 43 profiles are administered under its reputed 'Aarogyam' brand, which offers patients a suite of wellness and preventive health care tests.
The Company primarily operates its testing services through a fully automated Centralised Processing Laboratory (the CPL) and has expanded its operations to include a network of Regional Processing Laboratories (RPLs).
The company currently operates 25 RPLs, one in each of New Delhi, Coimbatore, Hyderabad, Kolkata, Bangalore, Bhopal, Mumbai Patna and Chennai, which process samples sourced from their respective regions.

FAQs for the comparison of null and Thyrocare Technologies Ltd

Which company has a larger market capitalization, Molbio Diagnostics Ltd or Thyrocare Technologies Ltd?

Market cap of Molbio Diagnostics Ltd is 14,262 Cr while Market cap of Thyrocare Technologies Ltd is 7,357 Cr

What are the key factors driving the stock performance of Molbio Diagnostics Ltd and Thyrocare Technologies Ltd?

The stock performance of Molbio Diagnostics Ltd and Thyrocare Technologies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Molbio Diagnostics Ltd and Thyrocare Technologies Ltd?

As of October 25, 2026, the Molbio Diagnostics Ltd stock price is INR ₹1237.65. On the other hand, Thyrocare Technologies Ltd stock price is INR ₹462.25.

How do dividend payouts of Molbio Diagnostics Ltd and Thyrocare Technologies Ltd compare?

To compare the dividend payouts of Molbio Diagnostics Ltd and Thyrocare Technologies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.